02.15.24 -- Novo Holdings Clarifies, But Competitors Circling Catalent

“Having been outsourcing to CDMOs for 20 years in the small molecule space, I see a distinct difference in technical performance compared to my mid-2000s CDMOs," says an executive. What's going on here?

Downstream bottlenecks are a growing problem for legacy chromatography processes that can't keep pace with more robust upstream output. BioPlan has been tracking alternatives and discusses them here.

Explore strategies on developing a functional equivalence model for single-use manufacturing equipment and assemblies for use in drug product manufacturing.

Antibody-based therapeutics are increasing in popularity. Analyze the hurdles of antibody development and manufacturing and explore exciting developments.

Explore the potential of mAbs in treating diverse conditions, from cancer to infectious diseases, and learn about their transformation from scientific breakthroughs to life-changing therapies.

Biopharma organizations often require aliquoting of materials to support their projects, but can be burdened by the timelines, costs, and risk of compromising materials.

In a recent episode of Business of Biotech, Philogen CEO Dr. Dario Neri sat down to explore his journey from academia to startups, as well as Philogen's own trajectory.

Characterizing Fab and Fc-Fusion proteins and developing robust manufacturing processes can help usher them to market and provide new treatment options for diseases currently challenging to treat.

Hear from some of the experts who were instrumental in developing the accelerated mAb development program and work with biotech companies on a daily basis to accelerate their production timelines.

Working with the right CDMO is vital for successful drug lifecycle management. We now serve more than half of the world’s leading biopharmas, helping to expedite access to life-saving biologics.

The NanoAssemblr® commercial formulation system is an automated, single-use system for the clinical and commercial production of LNPs under cGMP conditions.

Simtra currently has open capacity for liquid vial projects at both manufacturing sites and can support rapid tech transfer depending on the complexity of the project and the availability of raw materials.